Next-generation of selective histone deacetylase inhibitors

Area of Science:

• Epigenetics
• Pharmacology
• Oncology

Background:

• Histone deacetylases (HDACs) are validated epigenetic drug targets in cancer therapy.
• Histone deacetylase inhibitors (HDACis) have shown efficacy across various cancers.
• First-generation pan-HDACis, targeting multiple isoforms, can cause significant side effects.

Purpose of the Study:

• To provide a state-of-the-art overview of selective HDACis.
• To summarize strategies and achievements in the development of next-generation HDACis.
• To highlight the improved risk-benefit profiles of isoform-selective inhibitors.

Main Methods:

• Review of current literature on HDAC inhibitor development.
• Analysis of strategies for achieving class- or isoform-selectivity.
• Compilation of recent achievements in selective HDACi research.

Main Results:

• Next-generation HDACis focus on class- or isoform-selectivity.
• Selective HDACis offer potentially improved therapeutic outcomes.
• Significant progress has been made in developing targeted HDAC inhibitors.

Conclusions:

• Selective HDACis represent a promising advancement in epigenetic cancer therapy.
• Targeted inhibition of HDAC isoforms can mitigate side effects associated with pan-HDACis.
• Continued research into selective HDACis is crucial for optimizing cancer treatment.